1.
Gibellini L, De Biasi S, Bianchini E, et al.
Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets
in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016.
2.
Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg
J, Hvas CL,Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ,
Kjeldsen J,Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ,
Radford-Smith G, LawranceIC, Andrews JM, Ellard K, Bell SJ. Concentrations of
Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Gastroenterology. Jul;151(1):110-9, 2016.
3.
Jonathan GG, Beatriz AÁ, Nazco C GJ, Norberto BL,
Fernando GN. Plasma levels of trastuzumab in gastric cancer: Case report. J
Oncol Pharm Pract. Sep 23, 2016.
4.
Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of
Measuring Trough Levels and Antibodies against Infliximab in Patients with
Pediatric Inflammatory Bowel Disease. Gut Liver. Sep 9 2016.
5.
Chen L., et al., Efficient Production of a Bioactive
Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in
Transgenic Rice Callus. Frontiers in Plant Science August 2016 | Volume 7 |
Article 1156.
6.
Farkas K., et al.,
Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing
in ulcerative colitis. Journal of Crohn's and Colitis Advance Access
published April 21, 2016
7.
Gutiérrez A, Zapater P, Juanola O, Sempere L, García
M, Laveda R, Martínez A, Scharl M, González-Navajas JM, Such J, Wiest R, Rogler
G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of
Flare at Short Term in Patients with Crohn's Disease. Am J Gastroenterol.
Apr;111(4):529-40, 2016
8. Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho
Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after
Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr.
Jun; 19(2): 116–122, 2016.
9. Hayashi S, et al., Early Prognostic Factors
Associated with the Efficacy of Infliximab Treatment for Patients with
Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther
(2016) 3:155–166
10. Bortlik M., et al., Discontinuation of
anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a
prospective observation. Scandinavian Journal of Gastroenterology, 2016 vol.
51, no. 2, 196–202.
11. Al-Karkhi M.A., et al., Correlation
between Anti-infliximab and Anti-CCP Antibodies Development in Patients with
Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR
Journal of Dental and Medical Sciences, Volume 14, Issue 11 Ver. IV (Nov.
2015), PP 95-100.
12. Kui R, Gál B, Gaál M, Kiss M, Kemény L1, Gyulai R. Presence of antidrug
antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α
level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol.
Sep;43(9):1018-23, 2016
13.
Bodini G., Edoardo
G. Giannini, Edoardo V. Savarino, and Vincenzo Savarino. Adalimumab Trough
Levels and Response to Biological Treatment in Patients With Infl ammatory
Bowel Disease: A Useful Cutoff in Clinical Practice. Am J
Gastroenterol. Vol. 110, March,
2015.
14.
Juanola O., et
al., Anti-TNF-alpha loss of response is associated with a decreased percentage
of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease.
J Gastroenterol (2015) 50:758–768.
15. Fujita T, Murata Y, Hemmi S, Kajiwara M, Yabuki M, et al. (2015)
Persistent Complement Activation is Associated with Insulin Resistance and
Chronic Inflammation in Overweight Patients with Type 2 Diabetes with
Dyslipidemia. Int J Immunol Immunother 2:007, 2015
16. Malíckova K, et al., Serum trough infliximab levels: A comparison of
three different immunoassays for the monitoring of CT-P13 (infliximab)
treatment in patients with inflammatory bowel disease, Biologicals 2015.
17. Farkas K. et al, Efficacy of the new infliximab biosimilar CT-P13
induction therapy in Crohn’s disease and ulcerative colitis experiences from a
single center. Expert Opin. Biol. Ther. 15:(9) 2015.
18. Lee Y.M. et al, Infliximab ‘‘Top-Down’’ Strategy is Superior to
‘‘Step-Up’’ in Maintaining Long-Term Remission in the Treatment of Pediatric
Crohn Disease. JPGN 60: (737–743), 2015
19. Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in
Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243),
2015.
20. Bergen T.V., et al., Complementary effects of bevacizumab and MMC in the
improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmologica 2015, 667-678.
21. Aydın C, Ataoğlu H., Demonstration of β-1,2 Mannan Structures Expressed
on the Cell Wall of Candida albicans Yeast Form But Not on the Hyphal Form by
Using Monoclonal Antibodies Mikrobiyol Bul 49(1): 66-76, 2015.
22. Pallagi-Kunstár É. et al., Utility of serum TNF-a, infliximab trough
level, and antibody titers in inflammatory bowel disease. World J
Gastroenterol. 20(17): (5031-5035), 2014.
23. Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in
Inflammatory Bowel Disease. Gastroenterology & Hepatology, August
(478-489),2014.
24. Krajcovicova A. et al., Delayed hypersensitivity reaction after initial
dose of infliximab: a case report. European Journal of Gastroenterology&
Hepatology 26:(485-487), 2014.
25. Erdemli Ö., et al, In vitro evaluation of effects of sustained anti-TNF
release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis
synoviocytes.2014. Journal of Biomaterials Application, 29(4):524-42, 2014
26. Avdeeva A.A., Aleksandrova E.N., Karateev D.E., Luchikhina E.L., Novikov
A.A., Cherkasova M.V., Nasonov E.L. EFFICACY OF ADALIMUMAB IN EARLY RHEUMATOID
ARTHRITIS IN RELATION TO ITS SERUM LEVEL AND THE PRESENCE OF ANTI-DRUG
ANTIBODY. Rheumatology Science and Practice. 52(6):624–630. 2014 Russian, English abstract
http://rsp.ima-press.net/rsp/article/view/2007
27. Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies
Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term
Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014.
28. Jung Y et al., “Temperature-modulated noncovalent interaction
controllable complex for the long-term delivery of etanercept to treat
rheumatoid arthritis”, J. Control. Release 2013;
29. Gutierrez A, et al, Genetic susceptibility to
increased bacterial translocation influences the response to biological therapy
in patients with Crohn’s disease, Gut 0:1–9, 2013.
30. Grosen A., et al, Infliximab concentrations in the milk of nursing
mothers with inflammatory bowel disease, J Crohns Colitis 2013.
31. Romero G., et al, Poly(Lactide-co-Glycolide) Nanoparticles, Layer by
Layer Engineered for the Sustainable Delivery of AntiTNF-α. Macromol. Biosci.
13: (903–912), 2013.
32.
Cheong C, et al,
Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α
Contents and by Stimulating Newly Formed Neurogenesis, Mediators of
Inflammation, 2013; Volume 2013, Article ID 620837, 9 pages
http://dx.doi.org/10.1155/2013/620837
33.
Bortlik M et al,
“Pregnancy and newborn outcome of mothers with inflammatory bowel diseases
exposed to anti-TNF-a therapy during pregnancy: three-center study”,
Scandinavian Journal of Gastroenterology. 48: 951–958, 2013
34. Bortlik M, et al, Infliximab trough levels may predict sustained
response to infliximab in patients with Crohn's disease, Journal of Crohn's and
Colitis 2012.
35. Malickova K, et al, Phosphatidylserine-dependent
anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with
inflammatory bowel diseases, Autoimmun Highlights, 2012
36. Takahashi H, et al, Plasma trough levels of
adalimumab and infliximab in terms of clinical efficacy during the treatment of
psoriasis, Journal of Dermatology 2012; 39: 1- 4.
37. Seok Lee Y, et al, “Efficacy of Early Infliximab
Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up”, Pediatric
Gastroenterology, Hepatology & Nutrition 2012; 15(4):243-249
38. Molnar T, et al, “Importance of trough levels
and antibody titers on the efficacy and safety of Infliximab therapy in
inflammatory bowel disease”, Z Gastroenterol 2012; 50 - A53
39.
Kato S, et al,
“Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab
Maintenance Therapy in a Crohn’s Disease Patient”, Crohn’s & Colitis
Foundation of America 2011
40.
Adisen E, et al,
“Anti-infliximab antibody status and its relation to clinical response in
psoriatic patients”: A pilot study, Journal of Dermatology
2010; 37: 708–713.
